ArticleBMJ open respiratory research2026
Understanding real-world effectiveness of nirsevimab and the characteristics of breakthrough RSV infections: a study protocol of individual-participant-level data meta-analysis (the GEMINI study).
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe recent rollout of nirsevimab across multiple countries represents an important advancement in respiratory syncytial virus (RSV) prevention. However, real-world evidence on how its effectiveness varies with infant age and time since administration, and on the characteristics of breakthrough infections, remains limited. METHODS AND ANALYSIS: In this study, we aimed to conduct an international collaborative study to assess the real-world effectiveness of nirsevimab by monthly interval of chronological age and time since administration and to understand the characteristics of breakthrough infections. Both individual-participant-level data (IPD) and aggregated data will be collected from international collaborators identified by systematic review, existing collaborative network and academic conferences. The effectiveness of nirsevimab will be assessed by a test-negative study design, and a two-stage IPD meta-analysis will be conducted for data synthesis; a one-stage IPD meta-analysis will also be conducted among a subset of IPD data with sufficient sample size as an exploratory analysis. We will also describe the epidemiological, clinical and molecular features of breakthrough infections and compare them with infants and young children who were either unvaccinated and infected or vaccinated but not infected. The study will provide detailed insights into the dynamic effectiveness of nirsevimab and the characteristics of breakthrough cases. ETHICS AND DISSEMINATION: The study protocol has been approved by the Ethics Committee of Nanjing Medical University (2025-179). Ethical approval for the contributing studies is expected to be obtained independently by local investigators from their respective ethics committees. Findings will be presented at international conferences and submitted to peer-reviewed journals for publication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.